• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于接受不同类型基因组二级发现的大众观点:一项定性案例研究

Lay Perspectives on Receiving Different Types of Genomic Secondary Findings: a Qualitative Vignette Study.

作者信息

Vornanen M, Aktan-Collan K, Hallowell N, Konttinen H, Haukkala A

机构信息

Department of Social Research, University of Helsinki, Unioninkatu 37, P.O. Box 54, 00014, Helsinki, Finland.

Big Data Institute and the Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

出版信息

J Genet Couns. 2019 Apr;28(2):343-354. doi: 10.1007/s10897-018-0288-7. Epub 2018 Dec 14.

DOI:10.1007/s10897-018-0288-7
PMID:30964582
Abstract

Genome-wide sequencing may generate secondary findings (SFs). It is recommended that validated, clinically actionable SFs are reported back to patients/research participants. To explore publics' perspectives on the best ways to do this, we performed a vignette study among Finnish adults. Our aim was to explore how lay people react to different types of hypothetical genomic SFs. Participants received a hypothetical letter revealing a SF predisposing to a severe but actionable disease-cardiovascular disease (familial hypercholesterolemia, long QT syndrome) or cancer (Lynch syndrome, Li-Fraumeni syndrome). Participants (N = 29) wrote down their initial reactions, and discussed (N = 23) these in focus groups. Data were analyzed using inductive thematic analysis. Reactions to hypothetical SFs varied according to perceived severity and familiarity of the diseases. SFs for cancer were perceived as more threatening than for cardiovascular diseases, but less distressing than risk for psychiatric or neurological disorders, which participants spontaneously brought up. Illness severity in terms of lived experience, availability of treatment, stigma, and individual's responsibility to control risk were perceived to vary across these disease types. In addition to clinical validity and utility, SF reporting practices need to take into account potential familiarity and lay illness representations of different diseases. Illness representations may influence willingness to receive SFs, and individuals' reactions to this information.

摘要

全基因组测序可能会产生次要发现(SFs)。建议将经过验证的、具有临床可操作性的次要发现反馈给患者/研究参与者。为了探究公众对于实现这一目标的最佳方式的看法,我们在芬兰成年人中开展了一项 vignette 研究。我们的目的是探究外行人对不同类型的假设性基因组次要发现会作何反应。参与者收到一封假设性信件,其中揭示了一种易引发严重但可采取行动的疾病——心血管疾病(家族性高胆固醇血症、长 QT 综合征)或癌症(林奇综合征、李-佛美尼综合征)的次要发现。参与者(N = 29)写下他们的初始反应,并在焦点小组中(N = 23)进行了讨论。使用归纳主题分析法对数据进行了分析。对假设性次要发现的反应因对疾病的感知严重程度和熟悉程度而异。与心血管疾病相比,癌症的次要发现被认为更具威胁性,但比参与者自发提及的精神或神经疾病风险带来的痛苦要小。在这些疾病类型中,从实际生活经历来看的疾病严重程度、治疗的可及性、耻辱感以及个人控制风险的责任被认为各不相同。除了临床有效性和实用性之外,次要发现报告实践还需要考虑不同疾病潜在的熟悉程度和外行人对疾病的认知。

相似文献

1
Lay Perspectives on Receiving Different Types of Genomic Secondary Findings: a Qualitative Vignette Study.关于接受不同类型基因组二级发现的大众观点:一项定性案例研究
J Genet Couns. 2019 Apr;28(2):343-354. doi: 10.1007/s10897-018-0288-7. Epub 2018 Dec 14.
2
"I would like to discuss it further with an expert": a focus group study of Finnish adults' perspectives on genetic secondary findings.“我想与专家进一步讨论此事”:一项关于芬兰成年人对基因二次检测结果看法的焦点小组研究
J Community Genet. 2018 Jul;9(3):305-314. doi: 10.1007/s12687-018-0356-6. Epub 2018 Jan 16.
3
Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study.临床基因组测序的次要发现:来自多中心研究的患病率、患者观点、家族史评估和医疗保健成本。
Genet Med. 2019 May;21(5):1100-1110. doi: 10.1038/s41436-018-0308-x. Epub 2018 Oct 5.
4
Frequency of genomic secondary findings among 21,915 eMERGE network participants.eMERGE 网络 21915 名参与者中的基因组二级发现频率。
Genet Med. 2020 Sep;22(9):1470-1477. doi: 10.1038/s41436-020-0810-9. Epub 2020 Jun 17.
5
Parents perspectives on whole genome sequencing for their children: qualified enthusiasm?家长对为孩子进行全基因组测序的看法:有条件的热情?
J Med Ethics. 2017 Aug;43(8):535-539. doi: 10.1136/medethics-2016-103564. Epub 2016 Nov 25.
6
Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings.是否、何时、如何以及多少?一般公众和癌症患者对基因组二级发现披露的看法。
BMC Med Genomics. 2021 Jun 26;14(1):167. doi: 10.1186/s12920-021-01016-8.
7
Secondary findings in a large Pakistani cohort tested with whole genome sequencing.大巴基斯坦队列全基因组测序检测的次要发现。
Life Sci Alliance. 2023 Jan 12;6(3). doi: 10.26508/lsa.202201673. Print 2023 Mar.
8
International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: A systematic review.国际政策指导基因组测序中次生发现的选择、分析和临床管理:系统评价。
Am J Hum Genet. 2024 Oct 3;111(10):2079-2093. doi: 10.1016/j.ajhg.2024.08.012. Epub 2024 Sep 18.
9
Views of rare disease participants in a UK whole-genome sequencing study towards secondary findings: a qualitative study.英国全基因组测序研究中罕见病参与者对二级发现的看法:一项定性研究。
Eur J Hum Genet. 2018 May;26(5):652-659. doi: 10.1038/s41431-018-0106-6. Epub 2018 Feb 13.
10
Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment.临床基因组测序中偶然发现结果反馈的社会偏好:一项离散选择实验
CMAJ. 2015 Apr 7;187(6):E190-E197. doi: 10.1503/cmaj.140697. Epub 2015 Mar 9.

引用本文的文献

1
How does the genomic naive public perceive whole genomic testing for health purposes? A scoping review.公众对基于全基因组的健康检测持何种态度?——一项范围综述。
Eur J Hum Genet. 2023 Jan;31(1):35-47. doi: 10.1038/s41431-022-01208-5. Epub 2022 Oct 19.
2
Exploring the motivations of research participants who chose not to learn medically actionable secondary genetic findings about themselves.探讨选择不了解自身具有医学可采取的二级遗传发现的研究参与者的动机。
Genet Med. 2021 Dec;23(12):2281-2288. doi: 10.1038/s41436-021-01271-1. Epub 2021 Jul 29.
3
Taking it to the bank: the ethical management of individual findings arising in secondary research.
将其变为现实:二次研究中个体发现的伦理管理。
J Med Ethics. 2021 Oct;47(10):689-696. doi: 10.1136/medethics-2020-106941. Epub 2021 Jan 13.
4
Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.基于基因型的遗传性乳腺癌和卵巢癌风险检测方法,以及向生物库参与者披露风险的效果。
Eur J Hum Genet. 2021 Mar;29(3):471-481. doi: 10.1038/s41431-020-00760-2. Epub 2020 Nov 23.